Amaranth Medical Inc.
This article was originally published in Start Up
With technology developed at Nanyang Technological University. Amaranth has entered into an increasingly competitive race involving start-ups with their eyes on a considerable prize-the creation of a vascular stent composed of biodegradable polymers.
You may also be interested in...
Several interesting studies came out of this year's joint meeting of the American College of Cardiology and Society for Cardiovascular Angiography and Interventions. These studies--many of them about drug-eluting stents--will impact device manufacturers in both positive and negative ways.
Paris-based Arterial Remodeling Technologies is developing a bioabsorbable stent that may not require the use of anti-inflammatories.
Bioabsorbable Therapeutics, a start-up built around technology developed at Rutgers University, expects to begin conducting clinical trials on its bioabsorbable stent. The company, which is constructing the stents with polymers that contain non-sterioidal anti-inflammatories, is targeting the coronary market.